AstraZeneca's Tezspire improves eosinophilic esophagitis symptoms in Phase III trial

By Public Technologies
  • AstraZeneca and Amgen’s Tezspire met the Phase III CROSSING trial’s main goals in eosinophilic esophagitis, improving swallowing symptoms and tissue inflammation versus placebo.
  • Benefits persisted through one year; treatment also cleared visible signs of disease in some patients.
  • Results were presented at United European Gastroenterology Week 2026 in Barcelona, Spain.
  • The safety profile was consistent with existing indications.
  • AstraZeneca plans to share the findings with regulators to pursue Tezspire’s use in eosinophilic esophagitis.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief via Business Wire (Ref. ID: 202610200900BIZWIRE_USPR_____20261020_BW103666) on October 20, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.